Sonire Therapeutics Inc
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Private
- Established
- 2020-02-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 1
1 (50.0%)Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)
Phase 1
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Device: Suizenji (an ultrasound-guided HIFU therapy system)Drug: Nal-IRI/FLDrug: mFOLFIRINOX adjuvant chemotherapyDrug: Gem/nab-PTX
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- SONIRE Therapeutics Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT07033689
- Locations
- πΊπΈ
Stanford University, San Francisco, California, United States
A Study of Suizenji in Patients With Unresectable Pancreatic Cancer
Not Applicable
Recruiting
- Conditions
- Unresectable Pancreatic Cancer
- Interventions
- Drug: Nal-IRI/FLDevice: SuizenjiDrug: mFOLFIRINOXDrug: Gem/nab-PTX
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- SONIRE Therapeutics Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05601323
- Locations
- π―π΅
Aichi Medical University Hospital, Nagakute-shi, Aichi, Japan
π―π΅Tohoku University Hospital, Sendai-shi, Miyagi, Japan
π―π΅Tokyo Medical University Hospita, Shinjuku-ku, Tokyo, Japan
News
No news found